

Heesun Joyce Rogers

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1672807/heesun-joyce-rogers-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

913
citations

15
h-index

30
g-index

65
ext. papers

1,178
ext. citations

4.4
avg, IF

4.51
L-index

#	Paper	IF	Citations
59	Very rare Burkitt lymphoma with plasmacytoid differentiation, initial presentation as a CNS tumor, and poor prognosis. <i>International Journal of Laboratory Hematology</i> , 2021 ,	2.5	
58	Lymphocyte Cytosolic Protein 1 I232F Mutation Impairs Granulocytic Proliferation with a G2/M Block in Severe Neutropenia. <i>Blood</i> , 2021 , 138, 434-434	2.2	
57	Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML. <i>Blood</i> , 2021 , 138, 1295-1295	2.2	
56	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , 2021 , 137, 3685-3689	12	
55	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021 , 34, 1673-1685	9.8	5
54	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. <i>Modern Pathology</i> , 2021 , 34, 20-31	9.8	5
53	The hematology laboratory's response to the COVID-19 pandemic: A scoping review. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 148-159	2.5	4
52	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 735-738	1.9	2
51	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021 , 35, 3324-3328	10.7	0
50	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , 2021 , 91, 102595	2.1	1
49	Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020 , 95, 799-808	7.1	15
48	Severe megaloblastic anemia: Vitamin deficiency and other causes. <i>Cleveland Clinic Journal of Medicine</i> , 2020 , 87, 153-164	2.8	18
47	Myeloid neoplasm with eosinophilia and fusion. <i>Leukemia and Lymphoma</i> , 2020 , 61, 213-216	1.9	2
46	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. <i>International Journal of Laboratory Hematology</i> , 2020 , 42, 418-422	2.5	8
45	COVID-19 and the clinical hematology laboratory. <i>International Journal of Laboratory Hematology</i> , 2020 , 42 Suppl 1, 11-18	2.5	119
44	Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, e86-e88	2.5	2
43	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019 , 32, 1373-1385	9.8	14

42	Very unusual expression of multiple aberrant T-cell markers in plasmablastic plasma cell myeloma. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, e89-e91	2.5	2
41	Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. <i>Cancers</i> , 2019 , 11,	6.6	33
40	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019 , 32, 490-498	9.8	30
39	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <i>Modern Pathology</i> , 2018 , 31, 873-880	9.8	3
38	Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. <i>Modern Pathology</i> , 2018 , 31, 690-704	9.8	22
37	The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. <i>Blood Research</i> , 2018 , 53, 163-166	1.4	
36	JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. <i>British Journal of Haematology</i> , 2018 , 182, 78-85	4.5	15
35	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2017 , 102, 1352-1360	6.6	37
34	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017 , 30, 1213-1222	9.8	36
33	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 411-419	1.9	5
32	What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?: A Retrospective Analysis of 44 Patients With Serial SNP Arrays. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 278-284	1.9	1
31	Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. <i>Leukemia and Lymphoma</i> , 2016 , 57, 212-5	1.9	6
30	Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. <i>American Journal of Hematology</i> , 2016 , 91, E273-4	7.1	1
29	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 4301-4301	2.2	2
28	Thrombotic thrombocytopenic purpura: The role of ADAMTS13. <i>Cleveland Clinic Journal of Medicine</i> , 2016 , 83, 597-603	2.8	6
27	Targeting Autophagy in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 4295-4295	2.2	1
26	Recombinant α -Glycoprotein I (α GPI) Produced Using a Novel Lentiviral Approach Functions at Least As Well As Plasma-Derived α GPI in Detection of Anti- α GPI Antibodies. <i>Blood</i> , 2016 , 128, 2596-2596	2.2	2
25	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016 , 29, 854-64	9.8	74

24	Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. <i>Human Pathology</i> , 2016 , 52, 173-8	3.7	3
23	Cyclosporine dependent pure red cell aplasia: a case presentation. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 54, 281-3	2.1	
22	Acute parvovirus B19 infection detected in bone marrow biopsy. <i>Blood</i> , 2015 , 126, 1630	2.2	4
21	Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. <i>Blood</i> , 2015 , 126, 1647-1647	2.2	1
20	A History of Abnormal Bleeding Correlates with Platelet Dysfunction in Aggregation Studies but Not PFA-100 Analyses. <i>Blood</i> , 2015 , 126, 3447-3447	2.2	1
19	Platelet Function Testing Is Commonly Performed in Patients with Known Confounding Factors. <i>Blood</i> , 2015 , 126, 4726-4726	2.2	
18	Suboptimal Antiplatelet Therapy Suggested By Platelet Aggregation Studies Does Not Correlate with a Change in Clinical Management. <i>Blood</i> , 2015 , 126, 4634-4634	2.2	
17	Diastolic but Not Systolic Heart Failure Is Associated with Multiple Abnormalities on Platelet Aggregation Testing. <i>Blood</i> , 2015 , 126, 1079-1079	2.2	
16	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2014 , 123, 2645-51	2.2	145
15	Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). <i>American Journal of Hematology</i> , 2014 , 89, 862	7.1	9
14	Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. <i>Blood Research</i> , 2014 , 49, 85-94	1.4	51
13	Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. <i>Blood Research</i> , 2014 , 49, 216-27	1.4	38
12	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 89	22.4	16
11	Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. <i>Journal of Clinical Pathology</i> , 2014 , 67, 1093-8	3.9	8
10	Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia. <i>Blood</i> , 2014 , 124, 5597-5597	2.2	1
9	Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 (WASF3) Are Associated with Poor Prognosis in Myeloid Malignancies. <i>Blood</i> , 2014 , 124, 4600-4600	2.2	
8	Impact of Non-JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib. <i>Blood</i> , 2014 , 124, 3194-3194	2.2	
7	Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib. <i>Blood</i> , 2014 , 124, 1834-1834	2.2	1

6	Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q). <i>Blood</i> , 2014 , 124, 3250-3250	2.2	
5	Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis. <i>Blood</i> , 2014 , 124, 4587-4587	2.2	
4	Risk of Arterial and Venous Thrombosis in Patients with Indeterminate Lupus Anticoagulant Testing. <i>Blood</i> , 2014 , 124, 4249-4249	2.2	
3	Post Operative Thrombosis Among Patients Testing Indeterminate for Lupus Anticoagulant. <i>Blood</i> , 2014 , 124, 4255-4255	2.2	
2	Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). <i>Surgical Pathology Clinics</i> , 2013 , 6, 677-923,9	2	
1	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 3173-86	2.2	152